Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process

Transfusion

Volumn 51, Issue 11, 2011, Pages 2367-2376

  Cancelas, Jose A ^a,b,c   Dumont, Larry J ^a,b,c   Rugg, Neeta ^a,b,c   Szczepiorkowski, Zbigniew M ^a,b,c   Herschel, Louis ^a,b,c   Siegel, Alan ^a,b,c   Pratt, P Gayle ^a,b,c   Worsham, D Nicole ^a,b,c   Erickson, Anne ^a,b,c   Propst, Meisa ^a,b,c   North, Anne ^a,b,c   Sherman, Claire D ^a,b,c   Mufti, Nina A ^a,b,c   Reed, William F ^a,b,c   Corash, Laurence ^a,b,c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Dartmouth Hitchcock Medical School   (United States)

^c CERUS CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMIUM 51; LACTATE DEHYDROGENASE;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BLOOD GROUP TYPING; CELL LABELING; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; COOMBS TEST; CROSSOVER PROCEDURE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; ERYTHROCYTE METABOLISM; ERYTHROCYTE PRESERVATION; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; HYPERHIDROSIS; IN VITRO STUDY; IRON DEFICIENCY; ISOTOPE LABELING; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; NORMAL HUMAN; PAPULAR RASH; POSTTRANSFUSION RECOVERY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STOMACH PAIN; STREPTOMYCES VIOLACEUSNIGER; TORQUE TENO VIRUS INFECTION; TREATMENT OUTCOME;

EID: 79960186991     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2011.03163.x     Document Type: Article

References (41)

1. Anderson SA, Yang H, Gallagher LM, OCallaghan S, Forshee RA, Busch MP, McKenna MT, Williams I, Williams A, Kuehnert MJ, Stramer S, Kleinman S, Epstein J, Dayton AI,. Quantitative estimate of the risks and benefits of possible alternative blood donor deferral strategies for men who have had sex with men. Transfusion 2009; 49: 1102-14.
2. Wang B, Schreiber GB, Glynn SA, Kleinman S, Wright DJ, Murphy EL, Busch MP,. Retrovirus epidemiology donor study. Does prevalence of transfusion-transmissible viral infection reflect corresponding incidence in United States blood donors? Transfusion 2005; 45: 1089-96. (Pubitemid 40935006)
3. Kleinman S, Glynn SA, Busch M, Todd D, Powell L, Pietrelli L, Nemo G, Schreiber G, Bianco C, Katz L,. NHLBI Retrovirus Epidemiology Study (REDS). The 2003 West Nile virus United States epidemic: the Americas blood centers experience. Transfusion 2005; 45: 469-79.
4. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, Pappalardo B, Kleinman SH, NHLBI-REDS NAT Study Group. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005; 45: 254-64. (Pubitemid 40180144)
5. Cazenave JP, Isola H, Waller C, Mendel I, Kientz D, Laforêt M, Raidot JP, Kandel G, Wiesel ML, Corash L,. Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period. Transfusion 2011; 51: 622-9.
6. Osselaer JC, Doyen C, Defoin L, Debry C, Goffaux M, Messe N, Van Hooydonk M, Bosly A, Lin JS, Lin L, Corash L,. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 2009; 49: 1412-22.
7. Ruhl H, Bein G, Sachs UJ,. Transfusion-associated graft-versus-host disease. Transfus Med Rev 2009; 23: 62-71.
8. Hirayama J, Abe H, Azuma H, Ikeda H,. Leakage of potassium from red blood cells following gamma ray irradiation in the presence of dipyridamole, trolox, human plasma or mannitol. Biol Pharm Bull 2005; 28: 1318-20. (Pubitemid 41327612)
9. Mintz PD, Wehrli G,. Irradiation eradication and pathogen reduction. Ceasing cesium irradiation of blood products. Bone Marrow Transplant 2009; 44: 205-11.
10. Fergusson D, Khanna MP, Tinmouth A, Hebert PC,. Transfusion of leukoreduced red blood cells may decrease postoperative infections: two meta-analyses of randomized controlled trials. Can J Anaesth 2004; 51: 417-24.
11. Zhang X, Araki N, Ito K,. Post-transfusion alloimmunization to granulocytes and platelets in Japanese patients as determined by the MPHA method. Transfus Apher Sci 2001; 25: 163-72. (Pubitemid 33122119)
12. Hendrickson JE, Hillyer CD,. Noninfectious serious hazards of transfusion. Anesth Analg 2009; 108: 759-69.
13. Marik PE,. The hazards of blood transfusion. Br J Hosp Med (Lond) 2009; 70: 12-5.
14. Asano H, Lee CY, Fox-Talbot K, Koh CM, Erdinc MM, Marschner S, Keil S, Goodrich RP, Baldwin WM 3rd,. Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Transplantation 2007; 84: 1174-82. (Pubitemid 350125361)
15. -/- double knockout mice. Transfusion 2006; 46: 1553-60. (Pubitemid 44326331)
16. Grass JA, Wafa T, Reames A, Wages D, Corash L, Ferrara JL, Lin L,. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood 1999; 93: 3140-7. (Pubitemid 29200809)
17. Marschner S, Fast LD, Baldwin WM III, Slichter SJ, Goodrich RP,. White blood cell inactivation after treatment with riboflavin and ultraviolet light. Transfusion 2010; 50: 2489-98.
18. Corash L,. Inactivation of infectious pathogens in labile blood components: meeting the challenge. Transfus Clin Biol 2001; 8: 138-45. (Pubitemid 32672967)
19. Dupuis K, Bernard K, Jones S, Grellier P, Labaid M, van Voorhis W, Barrett L, Benach J, Monsalve G, Gil-GiL H, Sawyer L,. Helinx technology inactivates pathogens of emerging importance in red blood cell concentrates [abstract]. Blood 2003; 102 (Suppl 1): 816a (3020).
20. Hanson D, Propst M, Dupuis K, Schott MA, Stassinopoulos A,. High titer leukocyte inactivation in INTERCEPT red blood cells (RBC) [abstract]. Vox Sang 2001; 81: 101a.
21. Mikovits JA, Hagen K, Liu W, Hanson D, Sadowski C, Kewal-Ramani V, Lee K, Ruscetti FW, Lin L,. Inactivation of XMRV in platelet and RBC components prepared with the INTERCEPT blood system [abstract]. Rev Antivir Ther Infect Dis 2010; 8: 36-7 (Abs P-21).
22. Mufti NA, Erickson AC, North AK, Hanson D, Sawyer L, Corash LM, Lin L,. Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC. Biologicals 2010; 38: 14-9.
23. Rios JA, Hambleton J, Viele M, Rugg N, Sindermann G, Greenwalt T, Wages D, Cook D, Corash L,. Viability of red cells prepared with S-303 pathogen inactivation treatment. Transfusion 2006; 46: 1778-86. (Pubitemid 44435731)
24. Cancelas JA, Dumont L, Herschel L, Roger J, Rugg N, Garratty G, Arndt P, Propst M, Corash L, Laurence L, Sundin D, AuBuchon J,. A randomized, controlled, 2-period crossover study of recovery and lifespan of radiolabeled autologous 35-day old red blood cells prepared with a modified S-303 treatment for pathogen inactivation [abstract]. Vox Sang 2008; 95: 8-9 (2A-S01-03).
25. Benjamin RJ, McCullough J, Mintz PD, Snyder E, Spotnitz WD, Rizzo RJ, Wages D, Lin JS, Wood L, Corash L, Conlan MG,. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a phase III clinical trial in cardiac surgery patients. Transfusion 2005; 45: 1739-49. (Pubitemid 43923901)
26. Conlan MG, Vichinsky E, Snyder E, Goodnough LT, Labotka R, Eder A, Sloan SR, Minniti C, Lin J, Corash L,. S-303 pathogen inactivated red blood cells in patients with hemoglobinopathies participating in chronic transfusion programs: preliminary safety and efficacy results [abstract]. Vox Sang 2005; 89 (Suppl 1): 121 (T-PA-076).
27. Conlan MG, Stassinopoulos A, Garratty G, Wages D, Corash L, Wood L, Sloan SR, Labotka RJ,. Antibody formation to S-303-treated RBCs in the setting of chronic RBC transfusion [abstract]. Blood 2004; 104: 112-3 (382).
28. Moroff GS, Sohmer PR, Button LN,. Proposed standardization of methods for determining the 24-hour survival of stored red cells. Transfusion 1984; 24: 109-14. (Pubitemid 14135415)
29. International-Committee-for-Standardization-in-Haematology. Recommended method for radioisotope red-cell survival studies. Br J Haematol 1980; 45: 659-66.
30. AuBuchon JP, Cancelas JA, Herschel L, Roger J, Rugg N, Pratt PG, Joines A, Gormas JF, Zia M, Spearman MR,. In vitro and in vivo evaluation of LEUKOSEP HRC-600-C leukoreduction filtration system for red cells. Transfusion 2006; 46: 1311-5. (Pubitemid 44117957)
31. Mollison P,. The transfusion of red blood cells. In:, Klein HG, Anstee DJ, editors. Mollisons blood tranfusion in clinical medicine. 11th ed. Malden (MA): Blackwell Publishing Ltd. 2005, p. 352-405.
32. Abramowitz M, Stegun IA, editors. Handbook of mathematical functions with formulas, graphs, and mathematical tables. 9th ed. New York: Dover Publications; 1972. p. 885.
33. Cook D, Stassinopoulos A, Merritt J, Lin C, Reames A, Liu W, Schott M, Wang F, Alfonso R, Ling K, DuPuis K, Nerio A, Wilson K, Fang Y, Pu J, Singh Y, Wollowitz S,. Inactivation of pathogens in packed red blood cell (PRBC) concentrates using S-303 [abstract]. Blood 1997; 90 (Suppl 1): 409a (1820).
34. Cook D, Stassinopoulos A, Wollowitz S, Singh Y, Schott M, Wang F, Alfonso R, Lin C, Reames A, DuPuis K, Corten L, Ling K, Liu W, Tran Y, Merritt J, Johnson K, McCullough T,. In vivo analysis of packed red blood cells treated with S-303 to inactivate pathogens [abstract]. Blood 1998; 92 (Suppl 1): 503a (2070).
35. Conlan MG, Garratty G, Castro G, Erickson A, Schott MA, Arndt P, Cook D, Corash L, Stassinopoulos A,. Antibodies to S-303 treated red blood cells prepared with the original treatment process (OSRBC) for pathogen inactivation do not react with red blood cells prepared with a modified S-303 treatment process (MSRBC) [abstract]. Blood 2005; 106 (Suppl 1): 130a (430).
36. Lee L, Morfini M, Schulman S, Igerslev J,; and the Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. The design and analysis of pharmacokinetic studies of coagulation factors. 2001. [cited 2011 Apr 14]. Available at: URL
37. Lotter MG, Rabe WL, de Lange AH, Naudé H, Otto AC, Meyer B, Heyns AD, Badenhorst PN,. Reference values for red cell survival times. J Nucl Med 1991; 32: 2245-8.
38. Korell J, Coulter CV, Duffull SB,. A statistical model for red blood cell survival. J Theor Biol 2011; 268: 39-49.
39. Handin RI, Lux SE, Stossel TP, editors. Blood: principles and practice of hematology. 2nd ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2003. p. 2216-9.
40. Hess JR, Greenwalt TG,. Storage of red blood cells: new approaches. Transfus Med Rev 2002; 16: 283-95. (Pubitemid 35266246)
41. North AK, Lee V, Erickson A, Moore N,. Demonstration of an S-303-induced immune response in a naîve rabbit model of chronic transfusion using a sensitive flow cytometry assay. Vox Sang 2007; 93 (Suppl 1): 168.